⚠️ Important Medical Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice. The research discussed is preclinical (conducted in mice) and has not yet been tested in human clinical trials. Do not attempt to self-treat or self-medicate for Alzheimer’s disease or any neurological condition using cannabis or any combination of drugs without consulting a qualified healthcare professional. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition.
What the Study Found
A decade of research from one of Texas’s leading medical institutions has produced results that could reshape our understanding of cannabis and brain health.
The Research Team
Led by Dr. Chu Chen, PhD, a professor in the Department of Cellular and Integrative Physiology at UT Health San Antonio’s Long School of Medicine. Published in Aging and Disease, December 2025.
The Combination
Low-dose THC (ฮ9-tetrahydrocannabinol) combined with celecoxib, a COX-2 inhibitor commonly prescribed for arthritis. Both drugs are already FDA-approved for human use.
The Results
In mouse models, the THC-celecoxib combo improved cognition, learning, and memory while reducing beta-amyloid plaques, tau pathology, and neuroinflammation โ the hallmarks of Alzheimer’s disease.
Understanding the Science: How THC and Celecoxib Work Together
|
1
|
The THC ParadoxTHC has known anti-inflammatory and neuroprotective properties, but at certain doses it also activates an enzyme called COX-2 (cyclooxygenase-2) in the brain. This enzyme triggers inflammatory signaling that can impair learning and memory โ the very problems researchers aim to solve. |
|
2
|
Enter CelecoxibCelecoxib (brand name Celebrex) is a selective COX-2 inhibitor that has been prescribed for decades for arthritis and pain. By specifically blocking the COX-2 enzyme that THC activates, researchers hypothesized it could preserve THC’s benefits while eliminating its inflammatory side effects in the brain. |
|
3
|
The Combination WorksWhen administered together at low doses in mice for 30 days, the THC-celecoxib combination produced superior results: improved cognitive performance, reduced beta-amyloid plaques and tau tangles, and decreased neuroinflammation. Single-cell RNA sequencing confirmed that genes involved in brain health shifted back toward healthier profiles. |
|
4
|
Fast Track to Human TrialsBecause both THC (available as synthetic Marinol) and celecoxib are already FDA-approved for human use, the path to clinical trials could be significantly shorter than for experimental drugs still in development. Future studies will investigate whether the combination can also slow disease progression after symptoms appear. |
THC Alone vs. THC + Celecoxib: Head-to-Head Comparison
| Measure | THC Alone | THC + Celecoxib |
|---|---|---|
| Cognitive Performance | ✅ Improved | ✅ Significantly Improved |
| Learning & Memory | ✅ Improved | ✅ Better Outcomes |
| Beta-Amyloid Plaques | ✅ Reduced | ✅ Further Reduced |
| Tau Pathology | ✅ Reduced | ✅ Further Reduced |
| Inflammatory Signaling | ⚠️ Increased | ✅ Decreased |
| Gene Expression Profile | ➡️ Partial Shift | ✅ Shifted to Healthy |
| FDA-Approved Components | ✅ Yes (THC) | ✅ Yes (Both) |
Source: Zhang et al., “A Combination of Low-Dose ฮ9-THC and Celecoxib as a Therapeutic Strategy for Alzheimer’s Disease,” Aging and Disease, December 2025. Results from preclinical mouse models only.
Alzheimer’s Disease in America: By the Numbers
Why this research matters โ the scope of the Alzheimer’s crisis in the United States.
|
7.2M
Americans age 65+ living with Alzheimer’s in 2025 |
$384B
Projected healthcare costs in 2025 alone |
13.8M
Projected cases by 2060 without breakthroughs |
142%
Increase in Alzheimer’s deaths since 2000 |
Source: Alzheimer’s Association, 2025 Alzheimer’s Disease Facts and Figures Report.
What This Means for California Cannabis Consumers
|
💡
Evolving UnderstandingThis study adds to a growing body of research showing that cannabis compounds interact with our bodies in complex, dose-dependent ways that scientists are only beginning to understand. |
🛡
Low Dose Is KeyThe study used very low doses โ a human equivalent of approximately 18mg THC daily. This underscores the importance of microdosing principles and suggests that less may indeed be more. |
🛤
A Long Road AheadThese results are preclinical โ observed in mice, not humans. Clinical trials are needed before any conclusions can be drawn about effectiveness in people. A promising first step, not a cure. |
What the Researchers & Experts Are Saying
What really mattered was behavior. If cognition is not improved, then the treatment doesn’t matter. And that’s where the combination clearly worked better than THC alone.
Lead Researcher, UT Health San Antonio
This work has taken many years. But now we’re at a point where basic neuroscience discoveries are pointing toward something that could realistically move into the clinic.
On the path to clinical trials
Neurocognitive deterioration has been linked to conditions that cause inflammation within the brain. It makes sense that this combination therapy might help limit the production of amyloid and thereby reduce the progression of the disease.
Commentary via Fox News Health
What California Cannabis Consumers Are Saying
These are representative perspectives from community members discussing this research. They do not constitute medical endorsements.
|
“My grandmother has Alzheimer’s and watching her decline has been heartbreaking. Hearing that researchers are exploring cannabis-based approaches gives our family a small glimmer of hope for future treatments.” โ Rachel M., San Diego |
“I’ve been following cannabis research for years, and this study stands out because both drugs are already FDA-approved. That could mean faster clinical trials. Science is finally catching up with what many of us have felt intuitively about the plant.” โ David T., Los Angeles |
Understanding Alzheimer’s Disease
Watch this overview to better understand how Alzheimer’s disease affects the brain and why this research matters.
Frequently Asked Questions
Does this mean THC can cure Alzheimer’s disease?
No. This study was conducted in mice, not humans, and examined prevention of symptoms before they appeared โ not reversal of existing disease. While the results are promising, extensive human clinical trials are needed before any therapeutic claims can be made.
Can I use cannabis from a dispensary to prevent Alzheimer’s?
This study does not support self-treatment. The research used specific, controlled doses of pharmaceutical-grade THC combined with a prescription anti-inflammatory drug under laboratory conditions. Always consult with a healthcare professional before using any substance for medicinal purposes.
What is celecoxib and is it available without a prescription?
Celecoxib (brand name Celebrex) is a prescription NSAID that selectively inhibits the COX-2 enzyme. It is not available over the counter and requires a doctor’s prescription. It carries its own risks and side effects, including potential cardiovascular concerns at higher doses.
When might human clinical trials begin?
While no specific timeline has been announced, researchers noted that because both THC and celecoxib are already FDA-approved for human use, the path to clinical trials could be faster than for entirely new drugs.
What dose of THC was used in the study?
The mice received 3 mg/kg of THC and 1 mg/kg of celecoxib daily for 30 days. The human-equivalent dose would be approximately 18 mg of THC and 6 mg of celecoxib per day. However, these figures should not be used for self-medication. Note: Some scientists have debated the dose calculation methodology.
📚 Study Details & References
Full Citation: Zhang J, Zhu D, Hu M, Pan M, Chen C. “A Combination of Low-Dose ฮ9-THC and Celecoxib as a Therapeutic Strategy for Alzheimer’s Disease.” Aging and Disease. Published December 18, 2025.
Institution: Department of Cellular and Integrative Physiology, Joe R. and Teresa Lozano Long School of Medicine, UT Health San Antonio
Funding: National Institutes of Health (grant R01NS076815), Joe R. & Teresa Lozano Long School of Medicine startup and endowment funds
Alzheimer’s Statistics: Alzheimer’s Association, 2025 Alzheimer’s Disease Facts and Figures Report
ℹ️ Disclaimers: This article is published for informational and educational purposes only. It is not intended as medical advice and should not be construed as such. The study discussed herein is preclinical research conducted in animal models and has not been replicated in human clinical trials. Cannabis products sold at dispensaries are not equivalent to pharmaceutical-grade formulations used in research settings.
Vibe By California does not make any health claims regarding cannabis products. Consumers should consult with a qualified healthcare provider before making decisions about treating or preventing any medical condition. Cannabis use has risks and may not be appropriate for everyone.
Cannabis products are for use by adults 21 and older only in the State of California. Keep out of reach of children. The statements in this article have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
